EUSA Pharma is a pharmaceutical company developing and licensing late-stage oncology, pain control, and critical care products.
Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA.Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole®EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands.In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 28, 2007 | Series Unknown | $9.10M | 1 | — | — | Detail |
Nov 7, 2006 | Series Unknown | $18.60M | 4 | — | — | Detail |
Dec 13, 2005 | Series Unknown | $12.53M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Fort Mason Capital | — | Series Unknown |
Oppenheim Pramerica Asset Management | — | Series Unknown |
Little Gem Life Sciences Capital Management | — | Series Unknown |
Alexandra Investment Management | — | Series Unknown |
Downsview Capital | — | Series Unknown |